THARIMMUNE INC (THAR)

US4327053090 - Common Stock

2.39  +0.22 (+10.14%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to THAR. THAR was compared to 565 industry peers in the Biotechnology industry. The financial health of THAR is average, but there are quite some concerns on its profitability. THAR does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

THAR had negative earnings in the past year.
In the past year THAR has reported a negative cash flow from operations.
In the past 5 years THAR always reported negative net income.
THAR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

THAR's Return On Assets of -107.48% is on the low side compared to the rest of the industry. THAR is outperformed by 78.61% of its industry peers.
THAR has a Return On Equity of -132.58%. This is in the lower half of the industry: THAR underperforms 61.85% of its industry peers.
Industry RankSector Rank
ROA -107.48%
ROE -132.58%
ROIC N/A
ROA(3y)-188.86%
ROA(5y)-1021.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for THAR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

THAR has more shares outstanding than it did 1 year ago.
There is no outstanding debt for THAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -6.39, we must say that THAR is in the distress zone and has some risk of bankruptcy.
THAR's Altman-Z score of -6.39 is on the low side compared to the rest of the industry. THAR is outperformed by 67.56% of its industry peers.
There is no outstanding debt for THAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.39
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

THAR has a Current Ratio of 5.28. This indicates that THAR is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.28, THAR perfoms like the industry average, outperforming 57.58% of the companies in the same industry.
A Quick Ratio of 5.28 indicates that THAR has no problem at all paying its short term obligations.
With a Quick ratio value of 5.28, THAR perfoms like the industry average, outperforming 58.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.28
Quick Ratio 5.28

More info and screens

1

3. Growth

3.1 Past

THAR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.67%, which is quite impressive.
EPS 1Y (TTM)79.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, THAR will show a very strong growth in Earnings Per Share. The EPS will grow by 25.98% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.91%
EPS Next 2Y41.4%
EPS Next 3Y25.98%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for THAR. In the last year negative earnings were reported.
Also next year THAR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

THAR's earnings are expected to grow with 25.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.4%
EPS Next 3Y25.98%

More info and screens

0

5. Dividend

5.1 Amount

THAR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THARIMMUNE INC

NASDAQ:THAR (11/18/2024, 3:02:03 PM)

2.39

+0.22 (+10.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.56M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -107.48%
ROE -132.58%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.28
Quick Ratio 5.28
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)79.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y99.91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y